TP53 and hematopoietic and lymphoid cell neoplasm: Patients with prior hematologic cancer exhibited more adverse characteristics, including TP53 mutation, with a higher proportion classified as high to very high risk by IPSS-M, likely due to greater exposure to polychemotherapy, multiple lines of cytotoxic treatment, and high-risk genetic alterations.